These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 12583831)

  • 1. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.
    Pomerantz RG; Grandis JR
    Curr Oncol Rep; 2003 Mar; 5(2):140-6. PubMed ID: 12583831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting epidermal growth factor receptor in head and neck cancer.
    Ford AC; Grandis JR
    Head Neck; 2003 Jan; 25(1):67-73. PubMed ID: 12478546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Inhibition in Squamous Cell Carcinoma of the Head and Neck.
    Machiels JP; Schmitz S
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1011-32. PubMed ID: 26568545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor directed therapy in head and neck cancer.
    Choong NW; Cohen EE
    Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-targeting monoclonal antibodies in head and neck cancer.
    Astsaturov I; Cohen RB; Harari PM
    Curr Cancer Drug Targets; 2006 Dec; 6(8):691-710. PubMed ID: 17168674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR-targeting monoclonal antibodies in head and neck cancer.
    Astsaturov I; Cohen RB; Harari P
    Curr Cancer Drug Targets; 2007 Nov; 7(7):650-65. PubMed ID: 18045070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
    Modjtahedi H; Affleck K; Stubberfield C; Dean C
    Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual Targeting of Epidermal Growth Factor Receptor and HER3 by MEHD7945A as Monotherapy or in Combination with Cisplatin Partially Overcomes Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cell Lines.
    De Pauw I; Wouters A; Van den Bossche J; Deschoolmeester V; Baysal H; Pauwels P; Peeters M; Vermorken JB; Lardon F
    Cancer Biother Radiopharm; 2017 Sep; 32(7):229-238. PubMed ID: 28910149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current aspects of targeted therapy in head and neck tumors.
    Dietz A; Boehm A; Mozet C; Wichmann G; Giannis A
    Eur Arch Otorhinolaryngol; 2008 Jul; 265 Suppl 1():S3-12. PubMed ID: 18535834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
    Saba NF; Khuri FR; Shin DM
    Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.
    Ahmed SM; Cohen EE
    Curr Cancer Drug Targets; 2007 Nov; 7(7):666-73. PubMed ID: 18045071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress of squamous cell carcinoma of head and neck EGFR targeted therapy resistance mechanisms].
    Song Q; Li X
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jan; 29(2):184-90. PubMed ID: 25989677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer.
    Cruz JJ; Ocaña A; Del Barco E; Pandiella A
    Ann Oncol; 2007 Mar; 18(3):421-30. PubMed ID: 16873430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising new molecular targeted therapies in head and neck cancer.
    Dorsey K; Agulnik M
    Drugs; 2013 Mar; 73(4):315-25. PubMed ID: 23440867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.